- Title: Subtitle
- 1 - Primary Analysis of Zuma-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma
- Creators
- Frederick L. LockeDavid B. MiklosCaron A. JacobsonMiguel-Angel PeralesMarie José KerstenOlalekan O. OluwoleArmin GhobadiAaron P. RapoportJoseph P. McGuirkJohn M. PagelJavier MuñozUmar FarooqTom van MeertenPatrick M. ReaganAnna SuredaIan W. FlinnPeter VandenbergheKevin W. SongMichael DickinsonMonique C. MinnemaPeter A. RiedellLori A. LeslieSridhar ChagantiYin YangSimone FilostoMarco SchuppChristina ToPaul ChengLeo I. GordonJason R. Westin
- Resource Type
- Abstract
- Publication Details
- Transplantation and cellular therapy, Vol.28(3), pp.S1-S1
- DOI
- 10.1016/S2666-6367(22)00162-2
- ISSN
- 2666-6367
- eISSN
- 2666-6367
- Publisher
- Elsevier Inc
- Language
- English
- Date published
- 03/2022
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984362342702771
Abstract
1 - Primary Analysis of Zuma-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma
Transplantation and cellular therapy, Vol.28(3), pp.S1-S1
03/2022
DOI: 10.1016/S2666-6367(22)00162-2
Details
Metrics
24 Record Views